Bormioli Pharma Sustainability Profile
Bormioli Pharma, a leading name in the pharmaceutical packaging industry, is headquartered in Italy and operates extensively across Europe and beyond. Founded in 1927, the company has established itself as a pioneer in the design and production of glass and plastic containers, primarily serving the pharmaceutical, healthcare, and cosmetic sectors. Bormioli Pharma is renowned for its innovative solutions, including high-quality vials, bottles, and closures that ensure product safety and integrity. The company’s commitment to sustainability and advanced manufacturing processes sets it apart in a competitive market. With a strong focus on research and development, Bormioli Pharma has achieved significant milestones, solidifying its position as a trusted partner for global pharmaceutical companies.
DitchCarbon Score
How does Bormioli Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Paper Products industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Bormioli Pharma's score of 25 is higher than 56% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Bormioli Pharma's reported carbon emissions
In 2023, Bormioli Pharma reported total carbon emissions of approximately 134,185,000 kg CO2e for Scope 1 and 2, and about 95,334,000 kg CO2e for Scope 3 emissions. The Scope 3 emissions breakdown includes significant contributions from purchased goods and services (about 61,598,000 kg CO2e) and downstream transportation and distribution (approximately 11,428,000 kg CO2e). Bormioli Pharma has set ambitious reduction targets, aiming for a 30% reduction in CO2 emissions for both Scope 1 and Scope 2 by 2030, compared to 2021 levels. This commitment reflects the company's proactive approach to climate action and aligns with industry standards for sustainability. The emissions data is cascaded from its parent company, Bormioli Pharma S.p.a., which is part of a corporate family that includes Gerresheimer AG, indicating a structured approach to emissions reporting and climate commitments across the organisation.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|
| Scope 1 | - | - | - | - |
| Scope 2 | - | - | - | - |
| Scope 3 | - | - | 00,000,000 | 00,000,000 |
How Carbon Intensive is Bormioli Pharma's Industry?
How Carbon Intensive is Bormioli Pharma's Location?
Bormioli Pharma's Scope 3 Categories Breakdown
Bormioli Pharma's Scope 3 emissions, which increased by 13% last year and increased by approximately 13% since 2022, demonstrating supply chain emissions tracking. Their carbon footprint includes supplier sustainability and value chain emissions data across Scope 3 categories, with "Purchased Goods and Services" being the largest emissions source at 65% of Scope 3 emissions.
Top Scope 3 Categories
Bormioli Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Bormioli Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
